Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Trial Details

NCT ID

NCT06141226

Phase

PHASE2

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• TQB2450 +Anlotinib+Docetaxel
• TQB2450 +Androtinib Placebo+Docetaxel

Locations (sample)

• Huizhou, Guangdong, China|23.11147,114.41523
• Nanyang, Henan, China|33.00524,112.54659
• Lianyungang, Jiangsu, China|34.59845,119.21556
• Weihai, Shandong, China|37.50914,122.11356
• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• According to the International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancer, 8th editi…
• 18 years old ≤ age ≤ 75 years old; No gender limit; ECOG score 0-1 points; The expected survival period is ≥ 3 months.
• According to RECIST 1.1 standard, there should be at least one measurable lesion.
• Tumor resistance has progressed after receiving first-line treatment with immune checkpoint inhibitors (including PD-1 or PD-L1 monoclonal or dual …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.